Therapeutic benefit of the most expensive drugs covered by Medicare and Medicaid.

ABSTRACT:

Introduction

The United States began drug pricing negotiations in 2024 under the Affordable Care Act. Evaluating the therapeutic benefit of drugs will help guide pricing decisions and are an opportunity to improve healthcare affordability.

Discussion

We conducted a cross-sectional study of the 50 most expensive drugs by dosage unit covered by Medicare Part B, Medicare Part D, and Medicaid in 2022. We reported their level of clinical benefit as evaluated by health technology assessment agencies in France and Germany, their level of innovation as rated by the Food and Drug Administration of the United States, and their safety and effectiveness ratings as measured by Prescrire International, an independent French organisation that evaluates medicines. Our study found that among

SUBMITTER: Jiang TE 

PROVIDER: S-EPMC12490368 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature